Nomigrin (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium reduces inflammation by inhibiting cyclo‑oxygenase enzymes, lowering prostaglandin production. Sumatriptan succinate activates 5‑HT1B/1D receptors, causing cranial blood‑vessel constriction and blocking release of pain‑triggering neuropeptides, together aborting a migraine.

The specific dose and dosing schedule of Nomigrin are determined by the prescribing clinician based on the patient’s medical condition, severity of migraine, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Safety data for Nomigrin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nomigrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Nomigrin combines an NSAID with a triptan, offering both anti‑inflammatory and vasoconstrictive actions. Compared with single‑agent triptans, it may provide faster pain relief and reduce the need for additional analgesics, while offering a different safety profile than NSAID‑only regimens.

Nomigrin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children.

Nomigrin is taken orally with a full glass of water. It is usually administered at the first sign of a migraine attack, as directed by a healthcare professional. Swallow the tablet whole; do not crush or chew.

Serious risks include cardiovascular events such as chest pain, stroke, or myocardial infarction, severe allergic reactions, serotonin syndrome when combined with other serotonergic drugs, and significant hypertension. Patients should seek immediate medical attention if these occur.

Nomigrin is contraindicated in patients with known hypersensitivity to naproxen, sumatriptan, or any component of the formulation, as well as those with uncontrolled hypertension, recent myocardial infarction, severe coronary artery disease, or who are taking MAO inhibitors.